Skip to main content

Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 349-F4

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
349-F4-050

Key Product Details

Source

NS0

Accession #

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Binding Activity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human VEGFR3/Flt-4 protein
Human Flt-4
(Tyr25-Ile776) &
(Ser473-Ile776)
Accession # P35916
IEGRDMD Human IgG1
(Pro100-Lys330)
6-His tag
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Tyr25 & Ser473

Predicted Molecular Mass

112 kDa (monomer)

SDS-PAGE

145-150 kDa, 90-95 kDa and 75-80 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
Immobilized Recombinant Human VEGFR3/Flt‑4 Fc Chimera at 5 μg/mL (100 μL/well) binds Recombinant Human VEGF-D (Catalog # 622-VD) with an apparent Kd <15 nM.

Reviewed Applications

Read 1 review rated 5 using 349-F4 in the following applications:

Formulation, Preparation and Storage

349-F4
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 200 μg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR3/Flt-4

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt‑1) and VEGFR3 (Flt‑4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGFR3 (Flt‑4). VEGFR3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGFR3 may be important for lymph angiogenesis.

References

  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Long Name

Vascular Endothelial Growth Factor Receptor 3

Alternate Names

Flt-4, FLT4, VEGF R3

Entrez Gene IDs

2324 (Human); 14257 (Mouse)

Gene Symbol

FLT4

UniProt

Additional VEGFR3/Flt-4 Products

Product Documents for Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

For research use only

Loading...
Loading...
Loading...
Loading...